Phase I Trial of Bortezomib and “Non-Hybrid “(Bolus) Infusion Schedule of Alvocidib (Flavopiridol) in Patients with Recurrent or Refractory Indolent B-cell Neoplasms.
Holkova B et al. Clin Cancer Res. 2014 Sep 23. pii: clincanres.0805.2014. [Epub ahead of print].
Arsenic trioxide-based therapy in relapsed/refractory multiple myeloma patients: a meta-analysis and systematic review.
He X et al. Onco Targets Ther. 2014 Sep 10;7:1593-9. doi: 10.2147/OTT.S67165. eCollection 2014.
Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial.
San-Miguel JF et al. Lancet Oncol. 2014 Sep 18. pii: S1470-2045(14)70440-1. doi: 10.1016/S1470-2045(14)70440-1. [Epub ahead of print].
Panobinostat for the treatment of multiple myeloma.
Rajkumar SV. Lancet Oncol. 2014 Sep 18. pii: S1470-2045(14)70443-7. doi: 10.1016/S1470-2045(14)70443-7. [Epub ahead of print].
Phase I Study of 30-Minute Infusion of Carfilzomib As Single Agent or in Combination With Low-Dose Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma.
Papadopoulos KP et al. J Clin Oncol. 2014 Sep 15. pii: JCO.2013.52.3522. [Epub ahead of print].
Carfilzomib in multiple myeloma.
Andreu-Vieyra C et al. Expert Opin Biol Ther. 2014 Aug 29:1-15. [Epub ahead of print].